tiprankstipranks
Advertisement

HEAL - ETF AI Analysis

Compare

Top Page

HEAL

Global X HealthTech ETF (HEAL)

Rating:62Neutral
Price Target:
HEAL, the Global X HealthTech ETF, has a solid but not top-tier rating, reflecting a mix of strong leaders and some weaker names in its portfolio. High-quality holdings like Dexcom, GE Healthcare, and Resmed support the fund with strong financial performance, positive earnings commentary, and solid momentum, while positions such as Oscar Health and Philips weigh on the overall rating due to profitability challenges and weaker financial trends. The main risk is the fund’s focus on health technology, which concentrates exposure in a single, sometimes volatile sector where high valuations and occasional bearish technical signals can increase downside risk.
Positive Factors
Standout Top Holding
The fund’s largest position in Oscar Health has shown very strong gains this year, helping support overall performance despite weakness elsewhere.
Focused Health Tech Exposure
With most assets in health care and health technology companies, the ETF offers targeted access to a growing, specialized corner of the market.
Global Mix with U.S. Core
The ETF is anchored in U.S. stocks but also includes holdings from several other countries, adding some international diversification.
Negative Factors
Weak Recent Performance
The ETF has delivered negative returns so far this year and has also slipped slightly over the past month, signaling recent headwinds for the strategy.
Concentrated in Health Care
Because nearly all assets are in the health care sector, the fund is heavily exposed to sector-specific risks such as regulatory changes or reimbursement pressures.
Many Top Holdings Are Lagging
Several of the largest positions, including Pro Medicus, Veeva Systems, GE Healthcare, ResMed, and Insulet, have shown weak performance this year, which can drag on the fund’s returns.

HEAL vs. SPDR S&P 500 ETF (SPY)

HEAL Summary

The Global X HealthTech ETF (HEAL) follows the Global X HealthTech Index, focusing on companies that use technology to improve healthcare. It holds businesses involved in telemedicine, digital health platforms, and medical devices, mainly in the U.S. Well-known names in the fund include Dexcom and Philips, which make tools and systems that help doctors monitor and treat patients more efficiently. Someone might invest in this ETF to tap into the long-term growth of digital healthcare and add sector-focused diversification to their portfolio. A key risk is that it is heavily concentrated in health-tech stocks, so its price can swing more than the overall market.
How much will it cost me?The Global X HealthTech ETF (HEAL) has an expense ratio of 0.5%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized sector like health technology, which requires more research and expertise.
What would affect this ETF?The Global X HealthTech ETF (EDOC) could benefit from increasing demand for telemedicine and digital health solutions as healthcare systems worldwide continue to embrace technology for efficiency and accessibility. However, potential risks include regulatory changes in healthcare technology or slower adoption rates in certain regions, which could impact the growth of companies in its portfolio. Additionally, economic downturns or rising interest rates might negatively affect the performance of smaller, innovative firms within the ETF.

HEAL Top 10 Holdings

This ETF is a pure play on digital health, with most of its firepower in a handful of U.S.- and globally listed health-tech names. Veeva Systems and Dexcom are doing the heavy lifting, with rising share prices reflecting strong demand for cloud-based pharma tools and glucose monitoring tech. Tempus AI has also been a bright spot, adding some AI-fueled momentum. On the flip side, Oscar Health’s mixed fundamentals and Philips’ ongoing struggles are more of a drag, while Pro Medicus and GE Healthcare are treading water after a choppier run.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
IQVIA Holdings6.16%$1.92M$44.07B42.67%
73
Outperform
Veeva Systems5.94%$1.85M$44.54B0.79%
66
Neutral
Oscar Health5.85%$1.83M$9.96B65.98%
49
Neutral
Dexcom5.23%$1.63M$33.17B9.18%
79
Outperform
Pro Medicus Limited4.52%$1.41MAU$18.17B-38.74%
69
Neutral
Tempus AI, Inc. Class A4.21%$1.31M$11.66B-18.84%
52
Neutral
GE Healthcare Technologies Inc4.09%$1.28M$31.10B-9.07%
78
Outperform
Resmed4.01%$1.25M$32.94B-17.58%
76
Outperform
Hims & Hers Health3.63%$1.13M$6.47B-42.76%
68
Neutral
Waystar Holding Corp.3.59%$1.12M$4.81B-32.73%
68
Neutral

HEAL Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
28.49
Positive
100DMA
26.94
Positive
200DMA
27.40
Positive
Market Momentum
MACD
0.43
Positive
RSI
57.70
Neutral
STOCH
21.05
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HEAL, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 29.55, equal to the 50-day MA of 28.49, and equal to the 200-day MA of 27.40, indicating a bullish trend. The MACD of 0.43 indicates Positive momentum. The RSI at 57.70 is Neutral, neither overbought nor oversold. The STOCH value of 21.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HEAL.

HEAL Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$31.22M0.50%
62
Neutral
$51.88M0.50%
58
Neutral
$44.17M0.80%
64
Neutral
$33.21M0.44%
63
Neutral
$17.46M0.85%
65
Neutral
$13.78M0.55%
67
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HEAL
Global X HealthTech ETF
29.62
-2.65
-8.21%
FMED
Fidelity Disruptive Medicine ETF
MEDI
Harbor Health Care ETF
TMED
T. Rowe Price Health Care ETF
MEDX
Horizon Kinetics Medical ETF
BMED
Future Health ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement